|
Volumn 20, Issue 4, 2010, Pages 533-534
|
Pediatric primary cutaneous marginal zone B-cell lymphoma treated with intralesional rituximab
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CD20 ANTIGEN;
CD5 ANTIGEN;
CD79A ANTIGEN;
PROTEIN BCL 2;
PROTEIN BCL 6;
RITUXIMAB;
ANTINEOPLASTIC AGENT;
MONOCLONAL ANTIBODY;
B LYMPHOCYTE;
BONE MARROW BIOPSY;
BORRELIA BURGDORFERI;
CANCER REGRESSION;
CASE REPORT;
CELL INFILTRATION;
CELL NUCLEUS;
CELL STRUCTURE;
CHEEK;
CHILD;
CHILDHOOD CANCER;
COMPUTER ASSISTED EMISSION TOMOGRAPHY;
CYTOPLASM;
DERMIS;
DRUG EFFICACY;
DRUG SAFETY;
EPIDERMIS;
ESTHETICS;
EXCISION;
HUMAN;
IMMUNOFLUORESCENCE;
IMMUNOPHENOTYPING;
INFORMED CONSENT;
LETTER;
LYMPHOID CELL;
MALE;
MARGINAL ZONE LYMPHOMA;
MEDICAL HISTORY;
NUCLEOLUS;
POLYMERASE CHAIN REACTION;
SCHOOL CHILD;
SEROLOGY;
SKIN BIOPSY;
WESTERN BLOTTING;
INTRALESIONAL DRUG ADMINISTRATION;
LYMPHOMA, B-CELL;
SKIN NEOPLASMS;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
CHILD;
HUMANS;
INJECTIONS, INTRALESIONAL;
LYMPHOMA, B-CELL;
MALE;
SKIN NEOPLASMS;
ANTIBODIES, MONOCLONAL, MURINE-DERIVED;
|
EID: 77954725486
PISSN: 11671122
EISSN: 19524013
Source Type: Journal
DOI: 10.1684/ejd.2010.0987 Document Type: Letter |
Times cited : (28)
|
References (6)
|